This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Looking at the Peanut Allergy Landscape After Potentially the First FDA Approved Treatments

Ticker(s): AIMT, DBVT

Who's the expert?

Someone with experience from clinical trials with both DBVT and AIMT's products as well as a significant number of peanut allergy patients.

Interview Goal
This conversation will take place later in 2019 after the FDA potentially approves the first treatments for Peanut Allergy. The conversation will focus on real world experience of a clinician and his experience with patients. 

The conversation specifics will become more detailed one label and feedback becomes available, but the thrust of the conversation will be on the Peanut Allergy Landscape in late 2019.

Are You Interested In These Questions?



249Days Left to Join Project

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.